UBS analyst Trung Huynh lowered the firm’s price target on Amgen (AMGN) to $315 from $319 and keeps a Neutral rating on the shares. The firm notes a “strong” operational start to the year, but believes the investment in the pipeline growth tempers margin expansion, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue